BR0211079A - Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas - Google Patents

Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas

Info

Publication number
BR0211079A
BR0211079A BR0211079-2A BR0211079A BR0211079A BR 0211079 A BR0211079 A BR 0211079A BR 0211079 A BR0211079 A BR 0211079A BR 0211079 A BR0211079 A BR 0211079A
Authority
BR
Brazil
Prior art keywords
cells
processes
genetic modification
progenitor hematopoietic
methods
Prior art date
Application number
BR0211079-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Geoffery P Symonds
Rafael Amado
Lun-Quan Sun
Janet Macpherson
Greg Fanning
Wayne Gerlach
Original Assignee
Johnson & Johnson Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Res Pty Ltd filed Critical Johnson & Johnson Res Pty Ltd
Publication of BR0211079A publication Critical patent/BR0211079A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR0211079-2A 2001-07-10 2002-07-10 Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas BR0211079A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30428301P 2001-07-10 2001-07-10
US30412701P 2001-07-10 2001-07-10
US34348401P 2001-12-21 2001-12-21
US38606302P 2002-06-04 2002-06-04
PCT/US2002/021907 WO2003006691A1 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Publications (1)

Publication Number Publication Date
BR0211079A true BR0211079A (pt) 2005-08-30

Family

ID=27501852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211079-2A BR0211079A (pt) 2001-07-10 2002-07-10 Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas

Country Status (15)

Country Link
US (2) US7345025B2 (enExample)
EP (2) EP1414996B1 (enExample)
JP (2) JP5179697B2 (enExample)
KR (1) KR101015913B1 (enExample)
CN (2) CN1553963A (enExample)
AT (1) ATE490322T1 (enExample)
AU (1) AU2002316640C1 (enExample)
BR (1) BR0211079A (enExample)
CA (1) CA2453531A1 (enExample)
DE (1) DE60238486D1 (enExample)
DK (1) DK1414996T3 (enExample)
IL (2) IL159637A0 (enExample)
MX (1) MXPA04000268A (enExample)
NZ (1) NZ530624A (enExample)
WO (1) WO2003006691A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2190304A1 (en) * 1995-12-15 1997-06-16 Elazar Rabbani Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
KR101015913B1 (ko) 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
KR20040084885A (ko) * 2001-07-10 2004-10-06 존슨 앤드 존슨 리서치 피티와이 리미티드 형질도입된 조혈 선조 세포의 제조 방법
ES2358187T3 (es) * 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
WO2003022052A1 (en) * 2001-09-13 2003-03-20 California Institute Of Technology Method for expression of small rna molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US20040197316A1 (en) * 2003-02-06 2004-10-07 Tsokos George C. Novel method for the treatment of systemic lupus erythematosus
CA2519975C (en) * 2003-04-08 2013-07-02 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US7935074B2 (en) * 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
JP4268209B2 (ja) * 2005-07-20 2009-05-27 ソウル ナショナル ユニバーシティ インダストリー ファウンデーション 子宮内膜細胞を用いた造血幹細胞または前駆細胞の培養及び増殖方法
EP2032691A2 (en) * 2006-06-15 2009-03-11 Neostem, Inc Processing procedure for peripheral blood stem cells
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
CN102438631A (zh) * 2009-04-09 2012-05-02 史坦赛特股份有限公司 抗hiv干细胞及其用途
EP2453946B1 (en) 2009-07-15 2013-02-13 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
WO2012074068A1 (ja) * 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
US9694125B2 (en) 2010-12-20 2017-07-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
EP2699280B1 (en) 2011-04-21 2015-12-09 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
EP4193834B1 (en) * 2012-09-07 2025-05-14 Yale University Methods of using genetically modified mice
KR102402806B1 (ko) * 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
CA2893962C (en) 2012-12-06 2021-04-06 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
CN103471896A (zh) * 2013-09-09 2013-12-25 上海兰卫临床检验有限公司 革兰染色液质控品制备方法
US20200199534A1 (en) * 2017-04-27 2020-06-25 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
AU2018367546B2 (en) * 2017-11-15 2024-07-18 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
DE3852539T3 (de) 1987-12-15 2005-08-04 Gene Shears Pty. Ltd. Ribozyme.
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US4978514A (en) 1989-09-12 1990-12-18 Fuel Tech, Inc. Combined catalytic/non-catalytic process for nitrogen oxides reduction
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
CA2107789A1 (en) 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
ATE312510T1 (de) 1992-06-29 2005-12-15 Gene Shears Pty Ltd Nukleinsäuren und sie verwendende verfahren zur bekämpfung viraler pathogene
CA2154363A1 (en) 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
DK1298208T3 (da) 1994-01-05 2006-07-24 Gene Shears Pty Ltd Ribozymer der er målrettet mod en HIV-tat-sekvens
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
JPH11514209A (ja) 1995-04-20 1999-12-07 カイロン コーポレイション 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
US5741706A (en) * 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6060317A (en) 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
WO2000034495A2 (en) * 1998-12-04 2000-06-15 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
AU5403100A (en) * 1999-06-08 2000-12-28 Novartis Ag Enforced expression of bcl-xl
EP1317454B1 (en) 2000-09-13 2011-05-25 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP1354038A2 (en) 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
KR101015913B1 (ko) 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
ES2358187T3 (es) 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
KR20040084885A (ko) 2001-07-10 2004-10-06 존슨 앤드 존슨 리서치 피티와이 리미티드 형질도입된 조혈 선조 세포의 제조 방법
KR100646702B1 (ko) * 2001-08-16 2006-11-17 에스케이씨 주식회사 홀 및/또는 그루브로 형성된 화학적 기계적 연마패드

Also Published As

Publication number Publication date
WO2003006691A1 (en) 2003-01-23
EP1414996A4 (en) 2007-03-28
CN101926824A (zh) 2010-12-29
ATE490322T1 (de) 2010-12-15
US20080044394A1 (en) 2008-02-21
NZ530624A (en) 2009-02-28
JP2005528319A (ja) 2005-09-22
EP2322618A1 (en) 2011-05-18
US7776595B2 (en) 2010-08-17
JP5179697B2 (ja) 2013-04-10
IL159637A (en) 2013-07-31
AU2002316640C1 (en) 2009-01-29
HK1065074A1 (en) 2005-02-08
JP2010077125A (ja) 2010-04-08
AU2002316640B2 (en) 2008-06-12
US7345025B2 (en) 2008-03-18
IL159637A0 (en) 2004-06-01
EP1414996A1 (en) 2004-05-06
CN1553963A (zh) 2004-12-08
DK1414996T3 (da) 2011-03-21
MXPA04000268A (es) 2005-03-07
CA2453531A1 (en) 2003-01-23
KR20040032852A (ko) 2004-04-17
DE60238486D1 (de) 2011-01-13
EP1414996B1 (en) 2010-12-01
US20040072771A1 (en) 2004-04-15
KR101015913B1 (ko) 2011-02-23

Similar Documents

Publication Publication Date Title
BR0211079A (pt) Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas
EP1196444B8 (en) Exendin-4 conjugates and their medical use
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
EA200300536A1 (ru) Неограниченные соматические стволовые клетки (ussc), полученные из пуповинной крови человека
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
ES2249490T3 (es) Articulos quirurgicos.
DK1163904T3 (da) Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
SE9702860D0 (sv) New use
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
MY146351A (en) Compositions for treating infection in cattle and swine
BRPI0418157A (pt) terapêutica de tumores alogênicos
AU2378402A (en) Imaging, diagnosis and treatment of disease
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
IL181286A0 (en) Methods of healing wounds by administering human il-18
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
PT1150981E (pt) Composto nucleosidico terapeutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2262 DE 13/05/2014.